Anemia and iron deficiency in cancer patients: the role of intravenous iron supplements (a literature review)
- Authors: Sakaeva D.D.1,2
-
Affiliations:
- Bashkir State Medical University
- GC “Mother and Child”
- Issue: Vol 24, No 4 (2022)
- Pages: 468-476
- Section: CLINICAL ONCOLOGY
- URL: https://journals.rcsi.science/1815-1434/article/view/132981
- DOI: https://doi.org/10.26442/18151434.2022.4.202018
- ID: 132981
Cite item
Full Text
Abstract
Anemia in patients with malignancies is a common disorder that has a markedly negative impact on quality of life and overall prognosis. The pathogenesis of anemia is complex and multifactorial, depending on the type and stage of malignancy, nutritional status, renal function, age and gender, cytostatic drug, dose, and chemotherapeutic regimen, with iron deficiency often being the main and potentially treatable factor for anemia. In cancer patients, it can be caused by various concomitant mechanisms, including bleeding (e.g., in malignant gastrointestinal tumors or after surgery), malnutrition, medication, and hepcidin-induced iron sequestration in macrophages, with subsequent iron-deficient erythropoiesis. The variety of clinical manifestations of anemia makes it challenging to establish universal criteria to develop optimal treatments. Current therapy for anemia in malignant tumors includes replacement therapy with an iron supplement, erythropoiesis-stimulating agents (erythropoietins), and blood transfusions. However, blood transfusions should be minimized due to the high risks and costs. Therapy with an iron supplement is an effective approach to correcting the iron deficiency. It can increase the efficacy of erythropoiesis-stimulating drugs and reduce the need for blood transfusions. Published guidelines suggest the wide use of intravenous iron supplements. This article discusses possible approaches to treating iron deficiency in cancer patients in various clinical settings. We build on current guidelines and emphasize the need for further research in this area.
Full Text
##article.viewOnOriginalSite##About the authors
Dina D. Sakaeva
Bashkir State Medical University; GC “Mother and Child”
Author for correspondence.
Email: d_sakaeva@mail.ru
ORCID iD: 0000-0003-4341-6017
D. Sci. (Med.)
Russian Federation, Ufa; UfaReferences
- Ludwig H, Van Belle S, Barrett-Lee P, et al. The European cancer anaemia survey (ecas): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293-306. doi: 10.1016/j.ejca.2004.06.019
- Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathphysiology, and implications for contemroporary practis. International Journal of Clinical Transfusion Medicine. 2018;6:21-31. doi: 10.2147/IJCTM.S187569
- Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11S-26S. doi: 10.1016/j.amjmed.2003.12.008
- Grotto HZ. Anaemia of cancer: An overview of mechanisms involved in its pathogenesis. Med Oncol. 2008;25(1):12-21. doi: 10.1007/s12032-007-9000-8
- Gilreath JA, Stenehjem DD, Rodgers GM. Diagnosis and treatment of cancer-related anemia. Am J Hematol. 2014;89(2):203-12. doi: 10.1002/ajh.23628
- Langer CJ, Choy H, Glaspy JA, Colowick A. Standards of care for anemia management in oncology. Cancer. 2002;95(3):613-23. doi: 10.1002/cncr.10712
- Radziwon P, Krzakowski M, Kalinka-Warzocha E. Anemia in cancer patients-expert group recommendations. Oncol Clin Pract. 2017;13(5):202-10. doi: 10.5603/OCP.2017.0023
- Tas F, Eralp Y, Basaran M, et al. Anemia in Oncology Practice. Am J Clin Oncol. 2002;25(4):371-79. doi: 10.1097/00000421-200208000-00011
- Barrett-Lee PJ, Ludwig H, Birgegård G, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34-48. doi: 10.1159/000091675
- Clarke H, Pallister CJ. The impact of anaemia on outcome in cancer. Clin Lab Haematol. 2005;27(1):1-13. doi: 10.1111/j.1365-2257.2004.00664.x
- Bohlius J, Schmidlin K, Brillant C, et al. Erythropoietin or Darbepoetin for patients with cancer – meta-analysis based on individual patient data. Cochrane Database Syst Rev. 2009(3):CD007303. doi: 10.1002/14651858.CD007303.pub2
- Bamias A, Aravantinos G, Kalofonos C, et al. Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology. 2003;64(2):102-10. doi: 10.1159/000067766
- Pivot X, Guardiola E, Etienne M, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer. 2000;36(7):852-7. doi: 10.1016/s0959-8049(00)00010-1
- Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hemato- logy. Oncologist. 2009;14(Suppl. 1):43-56. doi: 10.1634/theoncologist.2009-S1-43
- Rothmann SA, Paul P, Weick JK, et al. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. Int J Cell Cloning. 1985;3(6):415-23. doi: 10.1002/stem.5530030607
- Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythro-poietin defciency syndrome. J Clin Invest. 1995;95(4):1650-9. doi: 10.1172/JCI117840
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst. 1999;91(19):1616-4. doi: 10.1093/jnci/91.19.1616
- Reitan JF, Kudrik FJ, Fox K, et al. The burden of blood transfusion: a utilization and economic analysis – a pilot study in patients with chemotherapy-induced anemia (CIA). J Med Econ. 2013;16(5):633-8. doi: 10.3111/13696998.2013.778269
- van Eeden R, Rapoport BL. Current trends in the management of anaemia in solid tumours and haematological malignancies. Curr Opin Support Palliat Care. 2016;10(2):189-94. doi: 10.1097/SPC.0000000000000209
- Harper P, Littlewood T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology. 2005;69(Suppl. 2):2-7. doi: 10.1159/000088282
- Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002;95(4):888-95. doi: 10.1002/cncr.10763
- Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol. 2007;25(9):1027-32. doi: 10.1200/JCO.2006.07.1514
- Ludwig H, Fritz E. Anemia in cancer patients. Semin Oncol. 1998;25(3 Suppl. 7):2-6.
- Adamson JW. The anemia of infammation/malignancy: mechanisms and management. Hematology Am Soc Hematol Educ Program. 2008:159-65. doi: 10.1182/asheducation-2008.1.159
- Skillings JR, Sridhar FG, Wong C, Paddock L. The frequency of red cell transfusion for anemia in patients receiving chemotherapy. A retrospective cohort study. Am J Clin Oncol. 1993;16(1):22-5. doi: 10.1097/00000421-199302000-00006
- Gaspar BL, Sharma P, Das R. Anemia in malignancies: Pathogenetic and diagnostic considerations. Hematology. 2015;20:18-25. doi: 10.1179/1607845414Y.0000000161
- Busti F, Marchi G, Ugolini S, et al Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018;11(4):94. doi: 10.3390/ph11040094
- Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001;91(12):2214-21.
- Schito L, Semenza GL. Hypoxia-inducible factors: Master regulators of cancer progression. Trends Cancer. 2016;2(12):758-70. doi: 10.1016/j.trecan.2016.10.016
- Deeb G, Vaughan, MM, McInnis I, et al. Hypoxia-inducible factor-1alpha protein expression is associated with poor survival in normal karyotype adult acute myeloid leukemia. Leuk Res. 2011;35(5):579-84. doi: 10.1016/j.leukres.2010.10.020
- Morine Y, Shimada M, Utsunomiya T, et al. Hypoxia inducible factor expression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 2011;58(110-111):1439-44. doi: 10.5754/hge11156
- Zheng SS, Chen XH, Yin X, Zhang BH. Prognostic significance of hif-1alpha expression in hepatocellular carcinoma: A meta-analysis. PLoS ONE. 2013;8(6):e65753. doi: 10.1371/journal.pone.0065753
- Semenza GL. Hif-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol Med. 2002;8(4 Suppl.):S62-7. doi: 10.1016/s1471-4914(02)02317-1
- Harrison LB, Chadha M, Hill RJ, et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist. 2002;7(6):492-508. doi: 10.1634/theoncologist.7-6-492
- Vaupel P, Harrison L. Tumor hypoxia: Causative factors, compensatory mechanisms, and cellular response. Oncologist. 2004;9(Suppl. 5):4-9 doi: 10.1634/theoncologist.9-90005-4
- Cella D, Dobrez D, Glaspy J. Control of cancer-related anemia with erythropoietic agents: A review of evidence for improved quality of life and clinical outcomes. Ann Oncol. 2003;14(4):511-9. doi: 10.1093/annonc/mdg167
- McCullough JJ. Complications in transfusion. In: Transfusion Medicine. 3rd ed. UK: Wiley-Blackwell, 2011.
- Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(Suppl. 3):12-8. doi: 10.1634/theoncologist.2011-S3-12
- Eder AF, Chambers LA. Noninfectious complications of blood transfusion. Arch Pathol Lab Med. 2007;131(5):708-18. doi: 10.5858/2007-131-708-NCOBT
- Hess JR. Red cell storage. J Proteomics. 2010;73(3):368-73. doi: 10.1016/j.jprot.2009.11.005
- Acheson AG, Brookes MJ, Spahn DR. Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: A systematic review and meta-analysis. Ann Surg. 2012;256(2):235-44. doi: 10.1097/SLA.0b013e31825b35d5
- Prescott LS, Taylor JS, Lopez-Olivo MA, et al. How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. Cancer Treat Rev. 2016;46:1-8. doi: 10.1016/j.ctrv.2016.03.010
- Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol. 2003;122(3):394-403. doi: 10.1046/j.1365-2141.2003.04448.x
- Smith RE Jr, Aapro MS, Ludwig H, et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008;26(7):1040-50. doi: 10.1200/JCO.2007.14.2885
- Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer. 2012;106(7):1249-58. doi: 10.1038/bjc.2012.42
- Rodgers GM, Gilreath JA. The role of intravenous iron in the treatment of anemia associated with cancer and chemotherapy. Acta Hematol. 2019;142(1):13-20. doi: 10.1159/000496967
- Girelli D, Ugolini S, Busti F, et al. Modern iron replacement therapy: Clinical and pathophysiological insights. Int J Hematol. 2018;107(1):16-30. doi: 10.1007/s12185-017-2373-3
- Coussirou J, Debourdeau A, Stancu A. Impact of ferric carboxymaltose on the evolution of hemoglobin and ecog performance status in iron-deficient patients with solid tumors: A 3-month follow-up retrospective study. Support Care Cancer. 2018;26(11):3827-34. doi: 10.1007/s00520-018-4250-x
- Kim YT, Kim SW, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105(1):199-204. doi: 10.1016/j.ygyno.2006.11.014
- Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116(3):522-5. doi: 10.1016/j.ygyno.2009.12.004
- Athibovonsuk P, Manchana T, Sirisabya N. Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy. Gynecol Oncol. 2013;131(3):679-82. doi: 10.1016/j.ygyno.2013.09.028
- Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol. 2013;24(2):475-82. doi: 10.1093/annonc/mds338
- Verhaeghe L, Bruyneel L, Stragier E, et al. The effectiveness of intravenous iron for iron deficiency anemia in gastrointestinal cancer patients: A retrospective study. Ann Gastroenterol. 2017;30(6):654-63. doi: 10.20524/aog.2017.0189
- Gafter-Gvili A, Rozen-Zvi B, Vidal L, et al. Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia – Systematic review and meta-analysis of randomised controlled trials. Acta Oncol. 2013;52(1):18-29. doi: 10.3109/0284186X.2012.702921
- Petrelli F, Borgonovo K, Cabiddu M, et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: A meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138(2):179-87. doi: 10.1007/s00432-011-1072-3
- Beguin Y, Aapro M, Ludwig H, et al. Epidemiological and nonclinical studies investigating effects of iron in carcinogenesis – A critical review. Crit Rev Oncol Hematol. 2014;89(1):1-15. doi: 10.1016/j.critrevonc.2013.10.008
- Wilson MJ, Dekker JWT, Buettner S, et al. The effect of intravenous iron therapy on long-term survival in anaemic colorectal cancer patients: Results from a matched cohort study. Surg Oncol. 2018;27(2):192-9. doi: 10.1016/j.suronc.2018.03.005
- Nairz M, Dichtl S, Schroll A, et al. Iron and innate antimicrobial immunity-depriving the pathogen, defending the host. J Trace Elem Med Biol. 2018;48:118-33. doi: 10.1016/j.jtemb.2018.03.007